Neuro Spectrum Insights, Inc.

S-1/A amended

Neuro Spectrum Insights, Inc. is conducting an IPO to commercialize GyriCalc™, a proprietary software for autism diagnosis using MRI analysis. The company received FDA marketing clearance in July 2025 and is targeting the U.S. and Canadian markets. The offering includes a public offering of shares and a potential resale by stockholders, with Network 1 Financial Securities Inc. as the sole underwriter. The company remains an emerging growth entity with no current revenue.

S-1/A amended

NeuroSpectrum Insights, Inc. is conducting an IPO to commercialize GyriCalc™, a proprietary software for autism diagnosis using MRI analysis. The company received FDA marketing clearance in July 2025 and is targeting the U.S. and Canadian markets. The offering includes a public offering of shares and a potential resale by stockholders, with Network 1 Financial Securities as the sole underwriter. The company remains an emerging growth entity with no revenue generated yet.

S-1/A amended

Neuro Spectrum Insights, Inc. has filed an S-1/A amendment for its IPO, detailing an initial public offering of common stock and a potential resale offering. The company's FDA-cleared product, GyriCalc, targets autism diagnosis using AI-driven MRI analysis. The filing highlights regulatory milestones, financial losses, and expansion plans for neurological disorder diagnostics. The company remains unprofitable and depends on a single product, with no revenue generated to date.

S-1 filed

NeuroSpectrum Insights, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to commercialize GyriCalc, a proprietary software tool for diagnosing autism via MRI analysis. The company, incorporated in 2016, has not yet generated revenue and is seeking FDA approval for its product. The IPO intends to list on the NYSE, with an expected price range of $[•] to $[•] per share. The filing includes two prospectuses: one for the public offering and another for potential resale by stockholders.

DRS filed

NeuroSpectrum Insights, Inc. is a medical device company preparing to commercialize GyriCalc, a computerized analysis technology for diagnosing neurological disorders like autism. The company is conducting an initial public offering (IPO) with a proposed share price range of $[•] to $[•], aiming to list on Nasdaq under the symbol [*]. The filing includes a Public Offering Prospectus and a separate Resale Prospectus for potential shareholder sales, with financial projections showing initial losses followed by projected revenue growth over five years. The company is an emerging growth company under the JOBS Act.